Skip to main content

Overview

Dr. Lotfi Chouchane is professor in the departments of genetic medicine, and microbiology and immunology of Weill Cornell Medicine.

Dr. Chouchane received his Ph.D. in immunology from Pasteur Institute of Paris and the University of Paris VII. Following a four-­year post-­doctoral position at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, in the U.S., he obtained his D. Sc. in human genetics and immunology. He then joined the National Institute of Medical Research in Paris as visiting scientist.

Before joining Weill Cornell Medicine, Prof. Chouchane was at the Faculty of Medicine of Monastir University in Tunisia, where he worked as professor of human genetics and immunology, and chief of the laboratory of immuno-­oncology. He was the chair of the department of basic science during the period between1996-­2002.

Highlights

  1. 1
    Hepatology (Baltimore, Md.) · 2022
    PMID: 35989577PMCID: PMC9869943DOISenior author26 citations
  2. 2
    The Lancet. Oncology · 2022
    PMID: 35150601DOISenior author24 citations
  3. 3
    JCI insight · 2021
    PMID: 33529170PMCID: PMC8021111DOIFirst author20 citations

Publications

166 publications

Funding

4 grants

Active

1 grant
  • PI
    ARG01-0529-230394: Single-Cell Multi-Omics, Organoid Engineering, and Animal Model to Unveil the Role of an Antioxidant Response System in the Pathogenesis of Autoimmune Thyroiditis
    Qatar National Research Fund · 2024–2027
    ARG01-0529-230394
Completed grants (3)
  • PI
    Exploring Drug Resistance Mechanisms in Triple Negative Breast Cancers: From Patient Derived Organoids towards Precision Medicine
    Qatar National Research Fund · 2021–2024
    PPM04-0311-200035
  • PI
    UBR5, E3 Ubiquitin Ligase, in Triple Negative Breast Cancers: Potential Role in Anti-Tumor Immunity and Cancer Metabolism
    Qatar National Research Fund · 2020–2024
    NPRP12S-0317-190379
  • PI
    Precision Immunology Implications for Aggressive Types of Breast Cancer: Genomic Determinants of Immune Response to Neoadjuvant Chemotherapy
    Qatar National Research Fund · 2016–2020
    NPRP 9-459-3-090

Available technologies